The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis
Open accessAbstract
Use of long-term constitutive expression of VEGF for therapeutic angiogenesis may be limited by the growth of abnormal blood vessels and hemangiomas. We investigated the relationship between VEGF dosage and the morphology and function of newly formed blood vessels by implanting retrovirally transduced myoblasts that constitutively express VEGF164 into muscles of adult mice. Reducing VEGF dosage by decreasing the total number of VEGF myoblasts implanted did not prevent vascular abnormalities. However, when clonal populations of myoblasts homogeneously expressing different levels of VEGF were implanted, a threshold between normal and aberrant angiogenesis was found. Clonal myoblasts that expressed low to medium levels of VEGF induced growth of stable, pericyte-coated capillaries of uniform size that were not leaky and became VEGF independent, as shown by treatment with the potent VEGF blocker VEGF-TrapR1R2. In contrast, clones that expressed high levels of VEGF induced hemangiomas. Remarkably, when different clonal populations were mixed, even a small proportion of cells with high production of VEGF was sufficient to cause hemangioma growth. These results show for the first time to our knowledge that the key determinant of whether VEGF-induced angiogenesis is normal or aberrant is the microenvironmental amount of growth factor secreted, rather than the overall dose. Long-term continuous delivery of VEGF, when maintained below a threshold microenvironmental level, can lead to normal angiogenesis without other exogenous growth factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
Polymeric system for dual growth factor delivery
Richardson, T. P., Peters, M. C., Ennett, A. B., & Mooney, D. J. (2001) · Nature Biotechnology · doi:10.1038/nbt1101-1029 · Cited by 1,752
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 2×
“VEGF-TrapR1R2, which consists of portions of the extracellular domains of VEGFR-1 and VEGFR-2 coupled to human Fc, is a soluble form of VEGF receptors that can be used to deplete active VEGF in vivo (30).”
BackgroundLutolf, M. P., Lauer-Fields, J. L., Schmoekel, H. G., Metters, A. T., Weber, F. E., Fields, G. B., & Hubbell, J. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737381100 · Cited by 1,508 · cited 1×
“These represent a diverse class of biomaterials that allow the homogeneous delivery of one or even two factors simultaneously (47, 48).”
BackgroundLeakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1
Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T. N., Yancopoulos, G. D., & McDonald, D. M. (1999) · Science · doi:10.1126/science.286.5449.2511 · Cited by 1,359
Self-citationAngiopoietin-1 protects the adult vasculature against plasma leakage
Thurston, G., Rudge, J. S., Ioffe, E., Zhou, H., Ross, L., Croll, S. D., Glazer, N., Holash, J., McDonald, D. M., & Yancopoulos, G. D. (2000) · Nature Medicine · doi:10.1038/74725 · Cited by 1,297
Self-citationHouck, K. A., Leung, D. W., Rowland, A. M., Winer, J., & Ferrara, N. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35712-0 · Cited by 1,127
Park, J. E., Keller, G. A., & Ferrara, N. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.12.1317 · Cited by 1,122
Lack of Pericytes Leads to Endothelial Hyperplasia and Abnormal Vascular Morphogenesis
Hellström, M., Gerhardt, H., Kalén, M., Li, X., Eriksson, U., Wolburg, H., & Betsholtz, C. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.3.543 · Cited by 1,100
Ackerman, L. V., & Rosaí, J. (1974) · Medical Entomology and Zoology · Cited by 1,043
Isner, J. M., Pieczek, A., Schainfeld, R., Blair, R., Haley, L., Asahara, T., Rosenfield, K., Razvi, S., Walsh, K., & Symes, J. F. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03361-2 · Cited by 989
Abnormalities in Pericytes on Blood Vessels and Endothelial Sprouts in Tumors
Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K., & McDonald, D. M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64920-6 · Cited by 983
Self-citationRando, T. A., & Blau, H. M. (1994) · The Journal of cell biology · doi:10.1083/jcb.125.6.1275 · Cited by 936
Self-citationIncreased Vascularization in Mice Overexpressing Angiopoietin-1
Suri, C., McClain, J., Thurston, G., McDonald, D. M., Zhou, H., Oldmixon, E. H., Sato, T. N., & Yancopoulos, G. D. (1998) · Science · doi:10.1126/science.282.5388.468 · Cited by 818
Self-citationAntonelli-Orlidge, A., Saunders, K. B., Smith, S. R., & D'Amore, P. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.12.4544 · Cited by 757
Brodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 745
VEGF Gene Delivery to Myocardium: Deleterious Effects of Unregulated Expression
Lee, R. J., Springer, M. L., Blanco-Bose, W. E., Shaw, R., Ursell, P. C., & Blau, H. M. (2000) · Circulation · doi:10.1161/01.cir.102.8.898 · Cited by 697
Self-citationClinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus: An Expert Panel Summary
Simons, M., Bonow, R. O., Chronos, N. A., Cohen, D. J., Giordano, F. J., Hammond, H. K., Laham, R. J., Li, W., Pike, M., Sellke, F. W., et al. (2000) · Circulation · doi:10.1161/01.cir.102.11.e73 · Cited by 459
Miquerol, L., Langille, B. L., & Nagy, A. (2000) · Development · doi:10.1242/dev.127.18.3941 · Cited by 429
Tie receptors: new modulators of angiogenic and lymphangiogenic responses
Jones, N., Iljin, K., Dumont, D. J., & Alitalo, K. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35067005 · Cited by 418
Pettersson, A., Nagy, J. A., Brown, L. F., Sundberg, C., Morgan, E., Jungles, S., Carter, R., Krieger, J. E., Manseau, E. J., Harvey, V. S., et al. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780013 · Cited by 417
Dor, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/21.8.1939 · Cited by 390
Tsurumi, Y., Takeshita, S., Chen, D., Kearney, M., Rossow, S. T., Passeri, J., Horowitz, J. R., Symes, J. F., & Isner, J. M. (1996) · Circulation · doi:10.1161/01.cir.94.12.3281 · Cited by 389
VEGF: an update on biological and therapeutic aspects
Ferrara, N. (2000) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00153-1 · Cited by 372
VEGF gene therapy: stimulating angiogenesis or angioma-genesis?
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/80430 · Cited by 370
Springer, M. L., Chen, A. S., Kraft, P. E., Bednarski, M., & Blau, H. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80154-9 · Cited by 363
Self-citationHirschi, K. K., Rohovsky, S. A., Beck, L. H., Smith, S. R., & D’Amore, P. A. (1999) · Circulation Research · doi:10.1161/01.res.84.3.298 · Cited by 340
The fate of individual myoblasts after transplantation into muscles of DMD patients
Gussoni, E., Blau, H. M., & Kunkel, L. M. (1997) · Nature Medicine · doi:10.1038/nm0997-970 · Cited by 330
Self-citationField, J., Nikawa, J.-I., Broek, D., MacDonald, B., Rodgers, L., Wilson, I. A., Lerner, R. A., & Wigler, M. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.5.2159-2165.1988 · Cited by 330
Drake, C. J., & Little, C. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7657 · Cited by 324
Isner, J. M. (2002) · Nature · doi:10.1038/415234a · Cited by 309
Mack, C. A., Patel, S. R., Schwarz, E. A., Zanzonico, P., Hahn, R. T., Ilercil, A., Devereux, R. B., Goldsmith, S. J., Christian, T. F., Sanborn, T. A., et al. (1998) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(98)70455-6 · Cited by 305
Mercadier, J.-J., & Logeart, D. (2002) · PubMed · Cited by 303
Schwarz, E. R., Speakman, M. T., Patterson, M., Hale, S. S., Isner, J. M., Kedes, L. H., & Kloner, R. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00522-2 · Cited by 272
Sundberg, C., Nagy, J. A., Brown, L. F., Feng, D., Eckelhoefer, I. A., Manseau, E. J., Dvorak, A. M., & Dvorak, H. F. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64062-x · Cited by 212
Takeshita, S., Tsurumi, Y., Couffinahl, T., Asahara, T., Bauters, C., Symes, J. F., Ferrara, N., & Isner, J. M. (1996) · PubMed · Cited by 211
Epstein, S. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00217-0 · Cited by 200
Mühlhauser, J., Merrill, M. J., Пили, Р., Maeda, H., Bacic, M., Bewig, B., Passaniti, A., Edwards, N. A., Crystal, R. G., & Capogrossi, M. C. (1995) · Circulation Research · doi:10.1161/01.res.77.6.1077 · Cited by 151
Assessment of Risks Associated With Cardiovascular Gene Therapy in Human Subjects
Isner, J. M., Vale, P. R., Symes, J. F., & Losordo, D. W. (2001) · Circulation Research · doi:10.1161/hh1701.096259 · Cited by 149
Blau, H. M., & Banfi, A. (2001) · Nature Medicine · doi:10.1038/87850 · Cited by 109
Self-citationSpringer, M. L., Rando, T. A., & Blau, H. M. (2001) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg1304s31 · Cited by 89
Self-citationThe Fate of Myoblasts Following Transplantation into Mature Muscle
Rando, T. A., Pavlath, G. K., & Blau, H. M. (1995) · Experimental Cell Research · doi:10.1006/excr.1995.1329 · Cited by 85
Self-citationHigh-efficiency retroviral infection of primary myoblasts
Springer, M. L., & Blau, H. M. (1997) · Somatic Cell and Molecular Genetics · doi:10.1007/bf02721371 · Cited by 78
Self-citationMagovern, C. J., Mack, C. A., Zhang, J. H., Rosengart, T. K., Isom, O. W., & Crystal, R. G. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.2-215 · Cited by 78
Localized arteriole formation directly adjacent to the site of VEGF-Induced angiogenesis in muscle
Springer, M. L., Ozawa, C. R., Banfi, A., Kraft, P. E., Ip, T.-K., Brazelton, T. R., & Blau, H. M. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00010-8 · Cited by 72
Self-citationAsh, J. D., & Overbeek, P. A. (2000) · Developmental Biology · doi:10.1006/dbio.2000.9755 · Cited by 70
A Novel Means of Drug Delivery: Myoblast-Mediated Gene Therapy and Regulatable Retroviral Vectors
Ozawa, C. R., Springer, M. L., & Blau, H. M. (2000) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.295 · Cited by 39
Self-citation
Cited by
Lutolf, M. P., & Hubbell, J. A. (2005) · Nature Biotechnology · doi:10.1038/nbt1055 · Cited by 4,551
A TALE nuclease architecture for efficient genome editing
Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1755 · Cited by 2,098
Why are tumour blood vessels abnormal and why is it important to know?
Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604929 · Cited by 611
Type H blood vessels in bone modeling and remodeling
Peng, Y., Wu, S., Li, Y., & Crane, J. L. (2020) · Theranostics · doi:10.7150/thno.34126 · Cited by 599
Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation
Baluk, P., Tammela, T., Ator, E., Lyubynska, N., Achen, M. G., Hicklin, D. J., Jeltsch, M., Petrova, T. V., Pytowski, B., Stacker, S. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522037 · Cited by 597
Self-citation
Metadata
- Authors
- Ozawa, C. R., Banfi, A., Glazer, N. L., Thurston, G., Springer, M. L., Kraft, P. E., McDonald, D. M., & Blau, H. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-02-15
- Volume
- 113
- Issue
- 4
- Pages
- 516-527
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2061940955
- Cited by
- 520
- References
- 50
- FWCI
- 11.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.